ClinicalTrials.gg
CompletedNCT04448431VIVREUpdated Feb 14, 2022

Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From Depression

A Phase 4 interventional study of Vortioxetine and Desvenlafaxine in Major Depressive Disorder, sponsored by H. Lundbeck A/S. Completed at 80 sites in 12 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-02-14.

Sponsored by H. Lundbeck A/S · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
605
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.

Enrollment
12th of 54
605 · median 413
Started
2020
with 2 others
Phase 4
13 of 54
none open now
Registered
50th of 54
by date
Lead sponsor
24 of 54
H. Lundbeck A/S

Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 12th largest by enrollment, is one of 3 that started in 2020, is one of 13 in phase 4, and was the 50th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vortioxetine

Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing vortioxetine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy of vortioxetine versus desvenlafaxine after 8 weeks of treatment in patients that have tried one available treatment without getting the full benefit

Read the detailed description

The study will consist of a screening period of up to 14 days before the Baseline Visit, followed by an 8-week Treatment Period with vortioxetine or desvenlafaxine. A Safety Follow-up Visit will be performed approximately 4 weeks after the Primary Outcome/Withdrawal Visit.

At Baseline, patients will be equally randomised (1:1) to 1 of the 2 treatment groups for an 8-week, double-blind Treatment Period.

03

Conditions studied

  • Major Depressive Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient has a primary diagnosis of single or recurrent MDD, diagnosed according to ®. The current MDE must be confirmed using the Mini International Neuropsychiatric Interview (MINI).
  • The patient has a MADRS total score ≥24 at screening and baseline.
  • The patient has had the current MDE for ≥3 months and \< 12 months.
  • The patient has been treated with an SSRI as monotherapy (citalopram, escitalopram, paroxetine, sertraline) for at least 6 weeks at licensed dose for the current MDE with a partial response and is a candidate for a switch in the investigator's opinion.
  • The patient wants to switch antidepressant treatment.

Exclusion criteria

Exclusion Criteria:

  • The patient has any other disorder for which the treatment takes priority over treatment of MDD or is likely to interfere with study treatment or impair treatment compliance.

Other in- and exclusion criteria may apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
605 participants (actual)

Study arms

  • Experimental
    Vortioxetine

    8 weeks treatment

    Drug: Vortioxetine

  • Active comparator
    Desvenlafaxine

    8 weeks treatment

    Drug: Desvenlafaxine

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Montgomery and Åsberg Depression Rating Scale (MADRS) total score

    The Montgomery and Åsberg Depression Rating Scale (MADRS) is a 10-item rating scale designed to assess the severity of the symptoms in depressive illness and to be sensitive to treatment effects. Symptoms are rated on a 7-point scale from 0 (no symptom) to 6 (severe symptom). The total score of the 10 items ranges from 0 to 60, with higher values indicating worse outcome.

    Time frame: From baseline to Week 8

Secondary outcomes

  1. Remission (defined as a MADRS total score =<10)

    The Montgomery and Åsberg Depression Rating Scale (MADRS) is a 10-item rating scale designed to assess the severity of the symptoms in depressive illness and to be sensitive to treatment effects. Symptoms are rated on a 7-point scale from 0 (no symptom) to 6 (severe symptom). The total score of the 10 items ranges from 0 to 60, with higher values indicating worse outcome.

    Time frame: At Week 8

  2. Response (defined as a => 50% decrease from baseline in MADRS total score)

    The Montgomery and Åsberg Depression Rating Scale (MADRS) is a 10-item rating scale designed to assess the severity of the symptoms in depressive illness and to be sensitive to treatment effects. Symptoms are rated on a 7-point scale from 0 (no symptom) to 6 (severe symptom). The total score of the 10 items ranges from 0 to 60, with higher values indicating worse outcome.

    Time frame: At Week 8

  3. Change in MADRS anhedonia factor score

    (based on items 1(apparent sadness),2 (reported sadness),6 (concentration difficulties),7 (lassitude),8 (inability to feel))

    Time frame: From baseline to Week 8

  4. Change in Digital Symbol Substitution Test (DSST) total score

    DSST assesses psychomotor speed of performance requiring visual perception, spatial decision-making, and motor skills. It consists of 133 digits and requires the patient to substitute each digit with a simple symbol in a 90-s period. Each correct symbol is counted, and the total score ranges from 0 (\< normal functioning) to 133 (\> normal functioning).

    Time frame: From baseline to Week 8

  5. The proportion number of Hard Choice/number of High Reward trials and number of Low choice/number of Low Reward trials when performing the Effort- Expenditure for Rewards Task (EEfRT)

    The EEfRT is a computerized task which measures reward motivation in which participants are presented with a series of repeated trials during which they choose between performing a ''hard-task'' or an ''easy-task'' in order to earn varying amounts of monetary rewards.

    Time frame: From baseline to Week 8

  6. Change in Clinical Global Impression - Severity of Illness (CGI-S) score

    The CGI-S scale measures the severity of psychiatric symptoms on a 7-point scale from 1-7. The scores indicated the following: 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants. The score ranged from 1-7, where 1 indicated absence of symptoms and higher score indicated greater severity of symptoms.

    Time frame: from baseline to Week 8

  7. Clinical Global Impression Scale- Global Improvement (CGI-I) score

    The Clinical Global Impression - global improvement CGI-I provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse)

    Time frame: at Day 7,28,56

  8. Change in Functioning Assessment Short Test (FAST) total score

    The FAST is a valid and reliable instrument, easy to apply which requires a short period of time to administer. Evaluates functioning taking into account the last 15 days. It was developed for the clinical evaluation of the main difficulties presented by psychiatric patients, and has been validated in several languages for patients with bipolar disorder. The FAST scale consists of 24 items which allow the assessment of six specific areas of functioning: autonomy, occupational functioning, cognitive functioning, financial issues, interpersonal relationships and leisure time

    Time frame: From baseline to Week 8

  9. Change in FAST sub-domain scores

    The FAST is a clinician-rated scale designed to assess difficulty in functioning. The FAST consists of 24 items in 6 specific areas of functioning: autonomy, occupational functioning, cognitive functioning, financial issues, interpersonal relationships, leisure time. Each item is rated on a 4-point scale from 0 (no difficulty) to 3 (severe difficulty). The items are summed to yield a total score ranging from 0 to 72 with higher scores reflecting more serious difficulties.

    Time frame: From baseline to Week 8

  10. Change in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) total score

    The original Q-LES-Q is a patient self-rated scale designed to measure the degree of enjoyment and satisfaction experienced by patients in various areas of daily life. It consists of 93 items to measure: physical health, feelings, work, household duties, school, leisure time activities, social relations, and general activities. Each item is rated on a 5-point scale ranging from 1 (very poor) to 5 (very good)

    Time frame: From baseline to Week 8

  11. Change in Q-LES-Q work subscale

    The original Q-LES-Q is a patient self-rated scale designed to measure the degree of enjoyment and satisfaction experienced by patients in various areas of daily life. It consists of 93 items to measure: physical health, feelings, work, household duties, school, leisure time activities, social relations, and general activities. Each item is rated on a 5-point scale ranging from 1 (very poor) to 5 (very good)

    Time frame: From baseline to Week 8

  12. Change in Q-LES-Q household duties subscale

    The original Q-LES-Q is a patient self-rated scale designed to measure the degree of enjoyment and satisfaction experienced by patients in various areas of daily life. It consists of 93 items to measure: physical health, feelings, work, household duties, school, leisure time activities, social relations, and general activities. Each item is rated on a 5-point scale ranging from 1 (very poor) to 5 (very good)

    Time frame: From baseline to Week 8

  13. Change in Q-LES-Q school/course subscale

    The original Q-LES-Q is a patient self-rated scale designed to measure the degree of enjoyment and satisfaction experienced by patients in various areas of daily life. It consists of 93 items to measure: physical health, feelings, work, household duties, school, leisure time activities, social relations, and general activities. Each item is rated on a 5-point scale ranging from 1 (very poor) to 5 (very good)

    Time frame: From baseline to Week 8

  14. Change in Q-LES-Q leisure time activities subscale

    The original Q-LES-Q is a patient self-rated scale designed to measure the degree of enjoyment and satisfaction experienced by patients in various areas of daily life. It consists of 93 items to measure: physical health, feelings, work, household duties, school, leisure time activities, social relations, and general activities. Each item is rated on a 5-point scale ranging from 1 (very poor) to 5 (very good)

    Time frame: From baseline to Week 8

  15. Change in Q-LES-Q social relations subscale

    The original Q-LES-Q is a patient self-rated scale designed to measure the degree of enjoyment and satisfaction experienced by patients in various areas of daily life. It consists of 93 items to measure: physical health, feelings, work, household duties, school, leisure time activities, social relations, and general activities. Each item is rated on a 5-point scale ranging from 1 (very poor) to 5 (very good)

    Time frame: From baseline to Week 8

07

Study locations

80 sites
  • Clinica Privada Banfield
    Banfield, Buenos Aires B1828CKR, Argentina
  • Cenydet-Centro Neurobiologico Y De Estres Traumatico-Biopsychomedical Research Group Srl
    Ciudad Autonoma De Buenos Aires, Buenos Aires C1058AAJ, Argentina
  • Fundacion para el Estudio y Tratamiento de las enfermedades mentales FETEM
    Ciudad Autonoma De Buenos Aires, Buenos Aires C1133AAH, Argentina
  • INAPsi (Instituto Nacional de Psicopatologia)
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1405BOA, Argentina
  • Clinica Privada De Salud Mental Santa Teresa De Avila
    La Plata, Buenos Aires 1900, Argentina
  • Instituto De Neurociencias San Agustin SA
    La Plata, Buenos Aires B1900BHE, Argentina
  • Sanatorio Prof. Leon S. Morra S.A.
    Cordoba, Providencia De Cordo X5009BIN, Argentina
  • CIAP (Centro de Investigacion y Asistencia en Psiquiatria)
    Rosario, Santa Fe 2000, Argentina
  • CINME (Centro de Investigaciones Metabolicas de Buenos Aires)
    Ciudad Autonoma De Buenos Aires, C1056ABJ, Argentina
  • CEN (Centro Especializado Neurociencias)
    Cordoba, 5000, Argentina
  • Instituto Modelo de Neurologia Fundacion Lennox
    Cordoba, X5000FAL, Argentina
  • Instituto Medico DAMIC - Fundacion Rusculleda
    Cordoba, X5003DCE, Argentina
  • Centro De Asistencia E Investigacion En Neurociencias CENAIN
    Mendoza, 5500, Argentina
  • Resolution Psicopharmacology Research Institute
    Mendoza, M5500BCR, Argentina
  • Algemeen Ziekenhuis St. Lucas-St. Jozef
    Brugge, 8310, Belgium
  • SINAPS - University Antwerpe- Psychiatrisch Ziekenhuis Duffel
    Duffel, 2570, Belgium
  • Cliniques De Mont-Godinne
    Yvoir, 5530, Belgium
  • MHAT Dr. Hristo Stambolski
    Kazanlak, 6100, Bulgaria
  • UMHAT Sv. Ivan Rilski EAD
    Plovdiv, 4002, Bulgaria
  • Center For Mental Health-Rousse
    Rousse, 7003, Bulgaria
  • MC Complete Medical Solutions
    Samokov, 2000, Bulgaria
  • Centre for Mental Health- Sofia
    Sofia, 1202, Bulgaria
  • Diagnostic Consultative Center Mladost-M Varna OOD
    Varna, 9020, Bulgaria
  • Clintrial s.r.o.
    Prague, Prague 10 100 00, Czechia
  • Dr.Jan Holan MD, Office of
    Brno, 61500, Czechia
  • Meditrine s.r.o. - Psychiatricka Ambulance, Lecebne Centrum
    Havirov, 73601, Czechia
  • Clinline services s.r.o.
    Hostivice, 25301, Czechia
  • Neuropsychiatrie HK, s.r.o.
    Hradec Kralove, 50009, Czechia
  • National Institute of Mental Health
    Klecany, 25067, Czechia
  • Psychiatricka Ambulance
    Kutna Hora, 28401, Czechia
  • A-Shine s.r.o.
    Plzen, 31200, Czechia
  • Institut neuropsychiatricke pece
    Praha 8, 18600, Czechia
  • Marienthali Kliinik
    Tallinn, 11315, Estonia
  • Psihiatrijas Centrs
    Liepaja, Liepajas Rajons 3401, Latvia
  • Riga Centre Of Psychiatry And Addiction Disorders
    Riga, 1005, Latvia
  • Sigulda Hospital Outpatient Clinic
    Sigulda, LV-2150, Latvia
  • CRI Centro Regiomontano de Investigacion SC
    Monterrey, Nuevo Leon 64060, Mexico
  • Medical Care and Research S.A. de C.V.
    Merida, Yucatan 97070, Mexico
  • Health Pharma Professional Research S.A. de C.V.
    Ciudad de Mexico, 03100, Mexico
  • Region Specialized Psychiatric Hospital No.2
    Stavropol Region, Kochubeev District 357034, Russian Federation
  • Leningrad Regional Psychoneurological Dispensary
    Roshchino, Leningrad Region 188820, Russian Federation
  • Arkhangelsk Regional Clinical Mental Hospital
    Arkhangelsk, 163530, Russian Federation
  • GUZ Engels Psychiatric Hospital
    Engels, 413124, Russian Federation
  • Moscow Scientific Research Institute of Psychiatry
    Moscow, 107076, Russian Federation
  • Clinic named after professor Yu. N. Kasatkin FGBOU DPO RMANPO Minzdrava Rossii
    Moscow, 125284, Russian Federation
  • Nizhny Novgorod Region State Institution Of Healthcare Clinical Psychiatric Hospital 1 Of Nizhny ...
    Nizhny Novgorod, 603155, Russian Federation
  • Rostov State Medical University of the Minzdravsotsrazvitiya of Russia
    Rostov-on-Don, 344022, Russian Federation
  • LLC Medical Center Nova Vita
    Rostov-on-Don, 344082, Russian Federation
  • Hospital OrKli , LLC
    Saint-Petersburg, 199178, Russian Federation
  • LLC Astarta
    Saint-Petersburg, 199226, Russian Federation
  • Saratov State Medical University
    Saratov, 410028, Russian Federation
  • State Budgetery Educational Institution Of Higher Professional Education Smolensk State Medical U...
    Smolensk, 214019, Russian Federation
  • St. Nicolas State Psychiatric Hospital
    St. Petersburg, 190121, Russian Federation
  • Yaroslavl Regional Clinical Psychiatry Hospital
    Yaroslavl, 150003, Russian Federation
  • Psychiatricka ambulancia, MENTUM, s.r.o.
    Bratislava, 82007, Slovakia
  • Epamed, S.R.O
    Kosice, 040 01, Slovakia
  • Psycholine S.R.O.
    Rimavska Sobota, 97901, Slovakia
  • Crystal Comfort, s.r.o.
    Vranov Nad Topou, 09301, Slovakia
  • BONA MEDIC s.r.o.
    Zlate Moravce, 95301, Slovakia
  • Psychiatricka Ambulancia
    Zlate Moravce, 95301, Slovakia
  • Centro De Salud Mental La Corredoria
    Oviedo, Asturias 33011, Spain
  • Hospital Universitario Fundacion Alcorcon
    Alcorcon, Madrid 28922, Spain
  • Hospital De La Santa Creu I Sant Pau
    Barcelona, 08041, Spain
  • Hospital Psiquiatric de Palma de Mallorca
    Palma de Mallorca, 07011, Spain
  • Smaert & Psykiatricentrum Malmoe
    Malmo, Skane 21137, Sweden
  • Affecta Psyikiatri AB
    Halmstad, 302 48, Sweden
  • ProbarE i Lund
    Lund, 22222, Sweden
  • ONE LIFETIME Lakarmottagning
    Skövde, 541 50, Sweden
  • ProbarE
    Stockholm, 11329, Sweden
  • Communal Non-commercial Enterprise Cherkasy regional psychiatric hospital of Cherkasy regional co...
    Smila, Cherkasy 20708, Ukraine
  • Communal Non-Commercial Enterprise of Kharkiv Regional Council Regional clinical psychiatric hosp...
    Kharkiv, Kharkivska 61068, Ukraine
  • Municipal Non-profit Enterprise Odesa Regional Psychiatric Hospital No.2 of Odesa Regional Council
    Kominternivskyy, Odesa 67513, Ukraine
  • CI of KRC Regional psychiatric and narcological medical association
    Glevakha, 8631, Ukraine
  • Ivano-Frankivsk Oblast neuropsychiatric hospital No. 3
    Ivano-Frankivsk, 76014, Ukraine
  • Academy of Medical Sciences of Ukraine - Institute of Neurology, Psychiatry and Narcology
    Kharkiv, 61068, Ukraine
  • SI INPN Namsu
    Kharkiv, 61068, Ukraine
  • Lviv Regional State Clinical Psychiatric Hospital, Lviv Danylo Galytsky National Medical University
    Lviv, 79021, Ukraine
  • Odessa Regional Medical Centre of Mental Health
    Odessa, 65006, Ukraine
  • Ukrainian Medical Stomatological Academy, Chair Of Psychiatry, Narcology And Medical Psychology B...
    Poltava, 36006, Ukraine
  • Vinnitsa National Medical University
    Vinnitsa, 21005, Ukraine
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Jan 2022, 18 months.

Of 98 phase 4 interventional studies under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 58. This study's 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2020
First posted
Jun 25, 2020
StartActual
Jun 18, 2020
Primary completionActual
Jan 6, 2022
CompletionActual
Feb 4, 2022
Last update
Feb 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04448431
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Jun 25, 2020
Start date
Jun 18, 2020
Primary completion
Jan 6, 2022
Completion
Feb 4, 2022
Last update
Feb 14, 2022

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@Lundbeck.com

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion